Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
A new study by Sandra Amaral and her team has found that children with chronic kidney disease (CKD), regardless of disease severity,...
Read Full NewsBritish lawmakers rejected on Friday a proposal to legalise assisted dying for terminally ill people, dealing a major setback to campaigners and bringing the latest effort...
In a global review, legalization was associated with increased cannabis use and related emergency department visits, with potential decreases in the use of alcohol and tobacco.
Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.
Patients who respond to neoadjuvant immunochemotherapy may be able to undergo less extensive surgery, with high rates of disease control and organ preservation.
In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.
For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.
1.
A US health panel advises starting mammograms at age 40 rather than 50.
2.
Infection Burden High With Myeloma T-Cell Therapies
3.
Study opens up possibility of bespoke prostate cancer treatment
4.
There is a 40% reduction in the risk of 9 cancers with good cardiorespiratory fitness.
5.
How Much of a Cancer Drug Is Too Much?
1.
Ear Emergency: Understanding the Causes and Treatment for Auricular Hematoma
2.
TAR-200 in Bladder Cancer: Precision Drug Delivery Driving Oncology Advances
3.
Interpreting Iron Studies: What Your Blood Results Really Mean
4.
Immune Ecosystem Remodeling Within Solid Tumor Niches
5.
The Benefits and Risks of Thrombolytics: A Comprehensive Guide
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part XV
2.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
3.
From Guidelines to Practice: Hematology
4.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge